Beam Therapeutics (NASDAQ: BEAM) and Ionis Pharmaceuticals (NASDAQ: IONS): two different competitive setbacks hit biotech names in same week. 11 July 2026 06:36 AM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key Highlights * Beam Faces Competitive Threat in AATD From Prime Medicine Arbitration Win: Arbitration awarding Prime Medicine the right to develop PM647 creates competitive uncertainty in Beam's key AATD program. * Ionis Loses ATTR-CM Competitive Position After Eplontersen Phase 3 Failure: The primary endpoint failure removes eplontersen as a ATTR-CM market contender, creating competitive void benefiting Alnylam and BridgeBio. * Both Companies Retain Buy-Rated Analyst Support Despite Material Setbacks: Analyst communities at both companies maintained positive ratings, highlighting ongoing pipeline value beyond the specific setback programs. Beam Therapeutics (NASDAQ: BEAM) and Ionis Pharmaceuticals (NASDAQ: IONS) both faced material competitive and clinical setbacks in the same week, illustrating the idiosyncratic and simultaneous risks that can affect biotech investors holding diversified positions across the gene therapy and antisense oligonucleotide technology platforms. Beam Therapeutics tumbled nearly 9% following the July 8 arbitration ruling that awarded rival Prime Medicine the right to develop PM647 for alpha-1 antitrypsin deficiency - injecting competitive uncertainty into the BEAM-302 AATD program just as the stock had recently touched a 52-week high near $38. BofA maintained its Buy rating with a $47 target, characterizing the ruling's impact as narrow and keeping analytical focus on BEAM-302 pivotal execution and the anticipated BEAM-101 BLA filing by year-end 2026. The arbitration ruling is binding, removing the possibility of a legal reversal, but BofA's characterization of the impact as narrow reflects confidence that Beam's base editing technology advantages can sustain competitive differentiation even with Prime Medicine entering the AATD field. Ionis Pharmaceuticals suffered a more severe setback: the CARDIO-TTRansform Phase 3 trial of eplontersen in ATTR cardiomyopathy patients failed to meet the primary endpoint of reducing cardiovascular mortality and recurrent cardiovascular events versus placebo. William Blair analysts described the failure as "surprising" given prior evidence supporting the combination approach, and the miss was followed by broad price target cuts: Morgan Stanley lowered to $110, Jefferies and Barclays each lowered to $90, and Citigroup (NYSE: C) lowered to $100 - though all maintained Buy or Overweight ratings reflecting confidence in the broader Ionis pipeline. The competitive beneficiaries of the Ionis failure are significant. Alnylam Pharmaceuticals (NASDAQ: ALNY), whose Amvuttra is approved for ATTR-CM, and BridgeBio Pharma (NASDAQ: BBIO), whose Attruby is an approved competing therapy, both stand to capture the market share Ionis had been expected to contest. AstraZeneca (NASDAQ: AZN) also fell on the shared setback, reflecting its involvement in the eplontersen development program. The simultaneous occurrence of competitive and clinical setbacks at two prominent biotech companies in the same week underscores the idiosyncratic and non-correlated nature of biotech investment risk - a reminder that portfolio-level biotech exposure requires diversification across programs and companies to manage the event-driven volatility that defines the sector. FAQs. Q: What are the key differences between Beam's and Ionis's setbacks? A: Beam Therapeutics' (NASDA Q: Which biotech companies benefit from Ionis's eplontersen Phase 3 failure? A: Alnylam Pharmaceuticals (NASDA Q: Why did analysts maintain Buy ratings at both companies despite the setbacks? A: Analysts maintained Buy ratings at both Beam Therapeutics (NASDA Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

Advanced cell-based therapy booming the success for healthcare sector. Mar 24, 2026, 10:00 ET Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /CNW/ - USANewsGroup.com - The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. But every cell-based therapy - no matter how revolutionary the science - begins with the same foundational requirement: a reliable, standardized bank of cells to work from. Without that cellular starting material, there is no consistency, no scalability, and no path from laboratory discovery to therapeutic development. A Master Cell Bank (MCB) is the process of taking a single genetically engineered cell and cloning it into tens of millions of identical copies under GMP-compliant conditions. It's the foundational infrastructure that ensures every subsequent step in therapy development works from the same characterized, quality-controlled source. It's not the therapy itself - it's the prerequisite that makes therapy development possible. That distinction matters, because the companies advancing cell therapies right now are each navigating their own version of the journey from cellular science to clinical reality. Prime Medicine (NASDAQ: PRME) is developing prime editing - a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing off-target risks that have haunted earlier CRISPR approaches. The precision is remarkable, but the path from edited cell to approved therapy is measured in years of development, trials, and manufacturing scale-up. Madrigal Pharmaceuticals (NASDAQ: MDGL) presented two-year data showing its therapy, Rezdiffra, significantly improved liver stiffness and fibrosis biomarkers in patients with compensated MASH cirrhosis - demonstrating that biological interventions can deliver sustained, measurable reversal of chronic organ damage. Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, the first approved tumor-infiltrating lymphocyte therapy for advanced melanoma. It's a landmark, but each treatment must be custom-manufactured from the individual patient's own tumor tissue - underscoring how critical scalable cellular infrastructure is to the future of the field. Denali Therapeutics (NASDAQ: DNLI) is advancing tividenofusp alfa for Hunter syndrome, with a PDUFA target date of April 2026 and multiple FDA designations, requiring precise protein engineering to cross the blood-brain barrier. Each of these programs illustrates the same truth: the distance between discovering a biological mechanism and delivering it to patients is defined by the quality of the cellular and manufacturing foundation underneath it. Avaí Bio (OTCQB: AVAI) recently announced the start of a key early-stage milestone alongside joint venture partner Austrianova: creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein. The MCB process clones a single engineered cell into tens of millions of identical copies, establishing the standardized cellular starting material from which all future working cell banks and therapy development for the Klothonova program will proceed. Prof. Walter H. Gunzburg, Chairman of Austrianova, said: "MCBs are a prerequisite for the production of Cell-in-a-Box(R) encapsulated cell products. They provide the foundation for sustainable production and ensure they meet the highest quality standards." The α-Klotho protein at the center of the Klothonova program is one of the most studied protective molecules in aging science. Peer-reviewed research links higher Klotho levels to reduced risk of Alzheimer's, cardiovascular disease, and certain cancers, while natural levels decline by approximately 50% after age 40. The addressable markets span Alzheimer's ($32.8 billion by 2033), cardiovascular disease (the world's leading cause of death), and kidney disease (850 million affected globally). Avaí Bio's dual-program approach also targets diabetes through the Insulinova platform, which, like Klothonova, leverages Austrianova's Cell-in-a-Box(R) encapsulation technology - a delivery system that protects therapeutic cells inside a biocompatible shell, allowing continuous protein secretion without immune rejection. The technology is backed by over 50 peer-reviewed publications. Every cell therapy begins with a single cell. The question is whether that cell has been properly characterized, cloned, and banked under the conditions required to support everything that comes after it. Avaí Bio (OTCQB: AVAI) just answered that question for its α-Klotho program - in a market heading toward $45 billion where the cellular foundation is what separates science from development. Read this and more news for Avaí Bio at: USANewsGroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avaí Bio, Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Avaí Bio, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avaí Bio, Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avaí Bio, Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.